⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 15, 2025Open Access

Figure 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Camila Bragança Xavier Clark R. Andersen JoAnn Lim Julian H. Slade Stacie A. Bean Lei Kang Hung Le Apostolia M. Tsimberidou Aung Naing David S. Hong Ecaterina E. Dumbrava Jordi Rodón Paula R. Pohlmann Sarina A. Piha‐Paul Stéphane Champiat Timothy A. Yap Tin‐Yun Tang Funda Meric‐Bernstam Siqing Fu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Kaplan–Meier curves illustrate overall survival rates for patients receiving PPIs in colorectal cancer.
Patients in the immunotherapy trials demonstrated varying outcomes depending on the drug interactions present.
The analysis highlights the significance of understanding drug interactions within solid tumor immunotherapy.
These findings may guide future treatment strategies by assessing drug interaction impacts on patient outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I unit evaluates immunotherapy outcomes in colorectal cancer, suggesting drug interactions may affect results.

Abstract

Kaplan–Meier OS curves for patients with colorectal cancer receiving PPIs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xavier et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa5865b https://doi.org/10.1158/2767-9764.30126789

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
2Data from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
3Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
4Figure 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit2025
5Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit2025 · 1 citations